Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck KGaA submits Erbitux MAA

As expected, Merck KGaA (FSE:MRK) submitted an MAA to the EMEA and the Swiss authority Swissmedic

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE